arrow
P

Patrycja Gradowska

erasmus university medical center cancer institute
H指数:15
被引数:1,972

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improved multistate survival in younger AML patients over time

年轻AML患者随时间推移的多状态生存改善

2026-11-030
OA
MDS/AML AND AML WITH MYELODYSPLASIA-RELATED GENE MUTATIONS: CLINICAL AND MOLECULAR SIMILARITIES

MDS/AML和AML伴骨髓增生异常相关基因突变: 临床和分子相似性

2026-01-160
OAAI
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia

流式细胞术基线可测残留病评估中定量下限作为低水平截断值的预后相关性研究

Leukemia
IF13.4
2025-12-100
OA
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients

高强度治疗患者中急性髓系白血病干细胞定量测定的不同特征。Haematologica

2025-12-012
OA
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial

急性髓系白血病中的计算性微小残留病评估:一项在HOVON-SAKK-132试验中的回顾性验证

Leukemia
IF13.4
2025-09-030
OAAI
A revised prognostic model for patients with acute myeloid leukemia and first relapse

针对急性髓系白血病首次复发的修订型预后模型

2025-05-260
OA
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

中等风险急性髓系白血病患者中可测量的残留疾病引导治疗是减少异基因移植而不影响生存的有价值的策略

2023-04-0612
OAAI
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
2022-10-103
OAAI
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

来那度胺在新诊断的年轻和中年AML患者的强化治疗中的补充: HOVON-SAKK-132试验

2021-02-2241
OA
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
2018-03-29606
OAAI